Search Results
Jul 08, 2025, 23:27 ET First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing novel ADCs, including bispecific ADC candidates, novel-payload ADC candidates, and autoimmune ADC candidates. For more information, please visit
More news about: Duality Biotherapeutics
Jul 08, 2025, 23:14 ET First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing novel ADCs, including bispecific ADC candidates, novel-payload ADC candidates, and autoimmune ADC candidates. For more information, please visit
More news about: Duality Biotherapeutics
Jul 08, 2025, 19:00 ET U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer
U.S. FDA grants Orphan Drug Designation to Adcentrx's ADRX-0405 STEAP1 ADC for the treatment of gastric cancerADRX-0405 is a STEAP1 ADC being evaluated in the Phase 1a portion of an ongoing Phase 1a/b clinical trial (
More news about: Adcentrx Therapeutics
Jul 07, 2025, 11:50 ET Cervical Cancer Treatment Market Size is Expected to Reach USD 14.91 Billion by 2030, with CAGR of 5.7%, Rising Prevalence of Cervical Cancer Fuels | The Insight Partners
Market FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical CancerFDA Fast-Tracks Novel ADC in Cervical CancerConclusion The cervical cancer treatment market is experiencing steady growth driven by increasing disease
More news about: The Insight Partners
Jul 04, 2025, 08:30 ET BioDlink Drives Global Biologics Innovation with Ecosystem Partners
patients more effective treatment options. A globalization playbook In a strategy roundtable, participants exchanged insights on ADC, TCE, and dual/multi-antibody project initiation strategies, innovative drug development target selection best practices, U.S. clinical trial navigation
More news about: BioDlink Biopharm Co., Ltd.
Jul 03, 2025, 17:31 ET GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight
2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ADC companies, including NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron
More news about: DelveInsight Business Research, LLP
Jul 03, 2025, 02:46 ET Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy
innovative bispecific ADCs, will further strengthen our leadership in the ADC 2.0 field. As a result, after the evolution of IO + chemotherapy, IO + ADC, and IO 2.0 + ADC, Akeso has once again created a global competitive edge in "IO+ADC" 2.0. We are excited about the potential of these next-generation treatments
More news about: Akeso, Inc.
Jul 02, 2025, 04:19 ET Arbele Wins Top Prize at BCIC's 4th Annual Biomedical Pitch Competition
engagers in solid tumors in Phase I clinical study. In addition to cabotamig, the company is advancing multiple ADC programs, including biparatopic and bispecific targets plus novel/dual payloads, with planned regulatory submissions
More news about: Arbele
Jul 01, 2025, 16:05 ET ADC Therapeutics Makes Grant to New Employee Under Inducement Plan
continued employment with the Company. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for
More news about: ADC Therapeutics SA
Jul 01, 2025, 14:14 ET Piramal Pharma Solutions avvia il piano di espansione da 90 milioni di dollari
sanitari sia dai pazienti. Allo stesso modo, le terapie ADC stanno guadagnando notevole popolarità, alimentate dall'innovazione continua, da una più ampia accettazione normativa e da solide prove che ne dimostrano l'efficacia. La crescente diffusione degli ADC sottolinea l'urgente necessità di ampliare le capacità
More news about: Piramal Pharma Ltd
Jul 01, 2025, 14:08 ET Piramal Pharma Solutions setzt ersten Spatenstich für Erweiterungsplan in Höhe von 90 Millionen USD
die derzeit erweitert werden, sind wesentliche Bestandteile des integrierten Angebots von Piramal Pharma im Bereich Antikörper-Wirkstoff-Konjugate (ADC), ADCelerate™. Sie spiegeln das Engagement des Unternehmens wider, innovative Lösungen anzubieten, die den Bedürfnissen der Patienten entsprechen. Piramal Pharma
More news about: Piramal Pharma Ltd
Jul 01, 2025, 02:45 ET LOBECO erweitert die Geschäftsführung: Dirk Huefnagels wechselt ab August in die Führungsriege der Münchner Digitalagentur
Seine Performance wurde mehrfach ausgezeichnet: Unter anderem erhielt er den renommierten Titel „Kunde des Jahres" vom Art Directors Club Deutschland (ADC). Neben seinen beruflichen Erfolgen engagierte sich Huefnagels auch ehrenamtlich. Als Vorstandsvorsitzender des Sponsorenverbands S20 setzte er sich
More news about: LOBECO
Jul 01, 2025, 01:45 ET Piramal Pharma Solutions inaugure un plan d'expansion de 90 millions de dollars
soins de santé et des patients. De même, les thérapies ADC gagnent considérablement en popularité, grâce à l'innovation continue, à une acceptation réglementaire plus large et à des preuves solides de leur efficacité. La prévalence croissante des ADC souligne le besoin pressant d'étendre les capacités de
More news about: Piramal Pharma Ltd
Jun 30, 2025, 08:59 ET Piramal Pharma Solutions inicia un plan de expansión de 90 millones de dólares
como entre los pacientes. De igual manera, las terapias con ADC están ganando terreno, impulsadas por la innovación continua, una mayor aceptación regulatoria y una sólida evidencia que demuestra su eficacia. La creciente prevalencia de los ADC subraya la apremiante necesidad de ampliar las capacidades
More news about: Piramal Pharma Ltd
Jun 30, 2025, 08:50 ET TuHURA Biosciences Completes Acquisition of Kineta
Officer of TuHURA. "The acquisition provides for synergies across both TuHURA's therapeutic focus as well as with TuHURA's antibody drug conjugate (ADC) technology. Not only can TBS-2025 be administered as the intact mAb alone or in combination with other therapeutics, we are also investigating the possibility
More news about: TuHURA Biosciences, Inc.
Jun 30, 2025, 04:21 ET Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
of each site. Both facilities undergoing expansions are essential components of Piramal Pharma's integrated antibody-drug conjugate (ADC) offering, ADCelerate™, reflecting the company's commitment to delivering innovative solutions that align with patient needs. Piramal
More news about: Piramal Pharma Ltd
Jun 30, 2025, 04:10 ET Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
of each site. Both facilities undergoing expansions are essential components of Piramal Pharma's integrated antibody-drug conjugate (ADC) offering, ADCelerate™, reflecting the company's commitment to delivering innovative solutions that align with patient needs. Piramal
More news about: Piramal Pharma Ltd
Jun 30, 2025, 00:04 ET Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
next-gen ADC pipeline, including: IBI343 (CLDN18.2 ADC): first in PDAC to demonstrate long-term survival benefits (mOS 12.1 months in 2L)IBI3001 (EGFR/B7H3 ADC): dual-targeted ADC with broad potential in solid tumorsIBI3020 (CEACAM5 dual payload ADC): designed
More news about: Innovent Biologics
Jun 26, 2025, 12:01 ET Global Cancer Immunotherapy Market Projected to Reach $247 Billion by 2029, Driven by 11.4% CAGR
viruses.Emerging startups Lytix BiopharmaAdaptimmuneADC Therapeutics SAY-mAbs Therapeutics, Inc.The report addresses the following questions: 1.
More news about: BCC Research LLC
Jun 26, 2025, 11:44 ET The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Citius Oncology, Inc. (NASDAQ: CTOR), ADC Therapeutics SA (NYSE: ADCT), and OS Therapies Incorporated (NYSE-American: OSTX).
More news about: USA News Group
Jun 25, 2025, 20:38 ET BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria
pipeline of more than 10 innovative drug candidates, including small molecules, monoclonal and bispecific antibodies, and antibody-drug conjugates (ADC). Currently, SC0062 a highly selective ETA antagonist owned by BioCity, is in development for CKD. A Phase 3 confirmatory trial for
More news about: BioCity Biopharma
Jun 25, 2025, 07:00 ET Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today
solid tumors (HRD/non-HRD), the NIH NExT Program is preparing three other protocols: CX-5461 with immunotherapy for colorectal cancer, CX-5461 with ADC, now a major focus in oncology innovation, for breast cancer and CX-5461 monotherapy for MYC-driven lymphomas. All three projects are underway, with
More news about: Senhwa Biosciences, Inc.
Jun 25, 2025, 07:00 ET Bio-Thera Solutions Announces First Patient Dosed in Phase 3 Clinical Trial for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Platinum-Resistant Ovarian Cancer
significant clinical challenge with poor patient prognosis and limited treatment options. Currently, only one FRα-targeting antibody-drug conjugate (ADC) is approved globally, and its indication is restricted to patients with FRα expression ≥75% (only 25%-30% of the platinum-resistant population). This
More news about: Bio-Thera Solutions, Ltd
Jun 24, 2025, 12:08 ET Ovarian Cancer Drugs Market Size expected to reach US$ 4.23 billion by 2031 | The Insight Partners
platinum-resistant epithelial ovarian cancer.FDA approved fast-track designation (FTD) for "RC88," a mesothelin-targeting antibody-drug conjugate (ADC) for the treatment of patients with recurrent epithelial ovarian cancer.The FDA announced approval for the SH-105 combination drug for the treatment
More news about: The Insight Partners
Jun 23, 2025, 07:55 ET OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer
lead clinical strategy and execution, leveraging his deep expertise to advance the company's lead Cadherin-6 (CDH6)-targeting antibody-drug conjugate (ADC) program, CUSP06, through clinical development. He will report to OnCusp's Chief Executive Officer, Bing Yuan, Ph.D. "Dr. Nuyten brings extensive
More news about: OnCusp Therapeutics